Clinical Trials
12 trialsNCT05114720 2025-12-17
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
Sun Yat-sen University
Phase 3 Completed
NCT01525394 2023-06-22
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
Eisai Inc.
Phase 1 Completed
NCT05481528 2023-05-09
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
Bayer
Phase 1 Completed
NCT03258515 2020-02-20
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
AstraZeneca
Phase 1 Completed
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT01874561 2016-10-10
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
Achieve Life Sciences
Phase 1 Completed
NCT02056392 2015-11-09
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT00398411 2015-06-29
MoxiProph
University of Cologne
Phase 3 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed
NCT00708903 2012-05-14
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
Puma Biotechnology, Inc.
Phase 1 Completed
NCT01302951 2011-02-24
MOXI
University Hospital, Saarland
Phase 4 Completed